The latest announcement is out from Genor Biopharma Holdings Limited ( (HK:6998) ).
Genor Biopharma Holdings Limited announced an extension to the deadlines for its substantial acquisition and proposed merger involving a reverse takeover and new listing application, moving the dates to June and December 2025 respectively. Additionally, the company has entered into a Cooperative Development Agreement with the Target, granting them rights to develop and commercialize two products globally, with Genor Biopharma set to receive royalties from any sales or cooperation involving these products. This strategic move is expected to enhance Genor Biopharma’s operational capacity and market presence.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a biopharmaceutical company incorporated in the Cayman Islands. The company focuses on developing, manufacturing, and commercializing pharmaceutical products worldwide, specifically targeting the treatment, diagnosis, and prevention of human and animal diseases.
YTD Price Performance: 7.37%
Average Trading Volume: 20,382
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €119.5M
For detailed information about 6998 stock, go to TipRanks’ Stock Analysis page.